Effect of Dexmedetomidine on Pharmacokinetics and Pharmacodynamics of Ropivacaine Following Lumbar Plexus Block

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900023934

Enrollment

Unknown

Registered

2019-06-19

Start date

2019-06-18

Completion date

Unknown

Last updated

2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar plexus block

Interventions

Group A:Ropivacaine 0.375%

Group B:Ropivacaine 0.375% + Dexmedetomidine 0.25

Group C:Ropivacaine 0.375% + Dexmedetomidine 0.5

Group D:Ropivacaine 0.375% + Dexmedetomidine 1.0

Group E:Ropivacaine 0.5%

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. signed the informed consent; 2. aged 18-60 years; 3. patients with unilateral lower extremity surgery; 4. BMI 18.5-28; 5. ASA I,II; 6. liver function: Child A; 7. The type of surgery is hip-joint replacement (total or hemihip replacement) or proximal femur fracture surgery

Exclusion criteria

Exclusion criteria: 1. secondary surgery; 2. liver and kidney dysfunction; 3. organic cardiopulmonary and brain diseases; 4. ropivacaine allergy; 5. abnormal coagulation function; 6. infection at puncture site; 7. peripheral neuropathy; 8. use of CYP1A2 or CYP3A4 inhibitors.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics Assessment;	—

Countries

China

Contacts

Public ContactYu Xiaoxia

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

yxx_xiao@126.com+86 13828479566

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026